Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics

Ultragenyx Pharmaceutical Inc. (RARE)

Today's Latest Price: $100.50 USD

5.50 (5.79%)

Updated Oct 30 4:00pm

Add RARE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

RARE Stock Summary

  • The ratio of debt to operating expenses for Ultragenyx Pharmaceutical Inc is higher than it is for about only 9.09% of US stocks.
  • RARE's price/sales ratio is 28.52; that's higher than the P/S ratio of 94.17% of US stocks.
  • Revenue growth over the past 12 months for Ultragenyx Pharmaceutical Inc comes in at 154.89%, a number that bests 96.23% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to RARE, based on their financial statements, market capitalization, and price volatility, are BLUE, AGIO, FPRX, RGNX, and APTX.
  • Visit RARE's SEC page to see the company's official filings. To visit the company's web site, go to www.ultragenyx.com.

RARE Stock Price Chart Interactive Chart >

Price chart for RARE

RARE Price/Volume Stats

Current price $100.50 52-week high $102.14
Prev. close $95.00 52-week low $31.99
Day low $93.84 Volume 1,256,000
Day high $102.14 Avg. volume 502,668
50-day MA $86.26 Dividend yield N/A
200-day MA $70.86 Market Cap 6.14B

Ultragenyx Pharmaceutical Inc. (RARE) Company Bio

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company was founded in 2010 and is based in Novato, California.

RARE Latest News Stream

Event/Time News Detail
Loading, please wait...

RARE Latest Social Stream

Loading social stream, please wait...

View Full RARE Social Stream

Latest RARE News From Around the Web

Below are the latest news stories about Ultragenyx Pharmaceutical Inc that investors may wish to consider to help them evaluate RARE as an investment opportunity.

New finance chief for Ultragenyx

Ultragenyx Pharmaceutical (RARE) has appointed Mardi C. Dier as EVP and CFO, effective November 2, 2020.Ms. Dier will succeed Ms. Sharp, who will remain as CFO until November and will consult for the company for six months after for smooth transition. Ms. Dier joins Ultragenyx from Portola Pharmaceuticals, where she...

Seeking Alpha | September 2, 2020

Ultragenyx Pharmaceutical Inc.'s (RARE) CEO Emil Kakkis on Q2 2020 Results - Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2020 Earnings Conference Call July 30, 2020 5:00 PM ET Company Participants Joshua Higa - Director, Investor Relations and Corporate Communications Emil Kakkis - Chief Executive Officer and President Erik Harris - Chief Commercial Officer Shalini Sharp - Chief Financial Officer Camille Bedrosian - Chief...

SA Transcripts on Seeking Alpha | July 31, 2020

Ultragenyx Pharmaceutical Inc (RARE) Q2 2020 Earnings Call Transcript

RARE earnings call for the period ending June 30, 2020.

Yahoo | July 31, 2020

Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates

Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.

Yahoo | July 31, 2020

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of 47.44% and 53.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2020

Read More 'RARE' Stories Here

RARE Price Returns

1-mo 17.26%
3-mo 28.58%
6-mo 55.28%
1-year 146.38%
3-year 109.42%
5-year -8.33%
YTD 135.31%
2019 -1.77%
2018 -6.25%
2017 -34.03%
2016 -37.32%
2015 155.65%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9805 seconds.